S&P 500   3,957.04 (+0.59%)
DOW   33,701.88 (+0.31%)
QQQ   283.40 (+1.02%)
AAPL   142.55 (+1.14%)
MSFT   246.99 (+1.07%)
META   115.77 (+1.62%)
GOOGL   94.18 (-0.80%)
AMZN   90.49 (+2.29%)
TSLA   173.65 (-0.22%)
NVDA   170.26 (+5.62%)
NIO   13.36 (+6.20%)
BABA   94.07 (+6.50%)
AMD   69.96 (-0.26%)
T   19.14 (-0.83%)
MU   55.14 (+2.45%)
CGC   3.03 (-6.48%)
F   13.12 (+0.15%)
GE   83.43 (-1.85%)
DIS   92.53 (+0.41%)
AMC   6.18 (+2.15%)
PYPL   74.59 (+0.23%)
PFE   51.54 (+2.59%)
NFLX   309.58 (+0.38%)
S&P 500   3,957.04 (+0.59%)
DOW   33,701.88 (+0.31%)
QQQ   283.40 (+1.02%)
AAPL   142.55 (+1.14%)
MSFT   246.99 (+1.07%)
META   115.77 (+1.62%)
GOOGL   94.18 (-0.80%)
AMZN   90.49 (+2.29%)
TSLA   173.65 (-0.22%)
NVDA   170.26 (+5.62%)
NIO   13.36 (+6.20%)
BABA   94.07 (+6.50%)
AMD   69.96 (-0.26%)
T   19.14 (-0.83%)
MU   55.14 (+2.45%)
CGC   3.03 (-6.48%)
F   13.12 (+0.15%)
GE   83.43 (-1.85%)
DIS   92.53 (+0.41%)
AMC   6.18 (+2.15%)
PYPL   74.59 (+0.23%)
PFE   51.54 (+2.59%)
NFLX   309.58 (+0.38%)
S&P 500   3,957.04 (+0.59%)
DOW   33,701.88 (+0.31%)
QQQ   283.40 (+1.02%)
AAPL   142.55 (+1.14%)
MSFT   246.99 (+1.07%)
META   115.77 (+1.62%)
GOOGL   94.18 (-0.80%)
AMZN   90.49 (+2.29%)
TSLA   173.65 (-0.22%)
NVDA   170.26 (+5.62%)
NIO   13.36 (+6.20%)
BABA   94.07 (+6.50%)
AMD   69.96 (-0.26%)
T   19.14 (-0.83%)
MU   55.14 (+2.45%)
CGC   3.03 (-6.48%)
F   13.12 (+0.15%)
GE   83.43 (-1.85%)
DIS   92.53 (+0.41%)
AMC   6.18 (+2.15%)
PYPL   74.59 (+0.23%)
PFE   51.54 (+2.59%)
NFLX   309.58 (+0.38%)
S&P 500   3,957.04 (+0.59%)
DOW   33,701.88 (+0.31%)
QQQ   283.40 (+1.02%)
AAPL   142.55 (+1.14%)
MSFT   246.99 (+1.07%)
META   115.77 (+1.62%)
GOOGL   94.18 (-0.80%)
AMZN   90.49 (+2.29%)
TSLA   173.65 (-0.22%)
NVDA   170.26 (+5.62%)
NIO   13.36 (+6.20%)
BABA   94.07 (+6.50%)
AMD   69.96 (-0.26%)
T   19.14 (-0.83%)
MU   55.14 (+2.45%)
CGC   3.03 (-6.48%)
F   13.12 (+0.15%)
GE   83.43 (-1.85%)
DIS   92.53 (+0.41%)
AMC   6.18 (+2.15%)
PYPL   74.59 (+0.23%)
PFE   51.54 (+2.59%)
NFLX   309.58 (+0.38%)
NASDAQ:NEO

NeoGenomics - NEO Stock Forecast, Price & News

$12.01
+0.43 (+3.71%)
(As of 12/8/2022 02:57 PM ET)
Add
Compare
Today's Range
$11.60
$12.07
50-Day Range
$6.45
$11.80
52-Week Range
$6.00
$35.40
Volume
29,986 shs
Average Volume
1.26 million shs
Market Capitalization
$1.52 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00

NeoGenomics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
57.8% Upside
$19.00 Price Target
Short Interest
Bearish
4.83% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.88) to ($0.69) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars

Medical Sector

467th out of 1,027 stocks

Testing Laboratories Industry

1st out of 1 stocks

NEO stock logo

About NeoGenomics (NASDAQ:NEO) Stock

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

Receive NEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter.

NEO Stock News Headlines

Why Shares of NeoGenomics Jumped 53.9% This Week
NeoGenomics (NEO) Reports Q3 Loss, Tops Revenue Estimates
NeoGenomics Reports Third Quarter 2022 Results
NeoGenomics, Inc. (NASDAQ: NEO)
Here’s How Artisan Partners Views NeoGenomics (NEO)
See More Headlines
Receive NEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter.

NEO Company Calendar

Last Earnings
11/04/2021
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/22/2023

Industry, Sector and Symbol

Industry
Testing laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NEO
Employees
2,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.00
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+58.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
12 Analysts

Profitability

Net Income
$-8,350,000.00
Pretax Margin
-35.84%

Debt

Sales & Book Value

Annual Sales
$484.33 million
Cash Flow
$0.20 per share
Book Value
$9.00 per share

Miscellaneous

Free Float
125,040,000
Market Cap
$1.52 billion
Optionable
Optionable
Beta
1.01

Key Executives

  • Mr. George A. CardozaMr. George A. Cardoza (Age 60)
    Pres & COO of Lab Operations
    Comp: $800.5k
  • Ms. Kathryn B. McKenzieMs. Kathryn B. McKenzie (Age 38)
    Interim Chief Culture Officer, Chief Sustainability & Risk Officer
    Comp: $793.48k
  • Mr. Christopher Michael Smith BSc (Age 59)
    CEO & Director
  • Mr. William Bishop Bonello (Age 57)
    Chief Financial Officer
  • Ms. Cynthia J. Dieter (Age 47)
    Chief Accounting Officer
  • Mr. John Mooney
    Chief Technology Officer
  • Dr. Shashikant Kulkarni Facmg
    M.B.A., M.S., Ph.D., Pres of Lab Operations & Chief Scientific Officer
  • Charlie Eidson
    Director of Investor Relations and Corp. Devel.
  • Mr. Hutan Hashemi J.D.
    Chief Compliance Officer
  • Ms. Ali Olivio
    Gen. Counsel & Corp. Sec.













NEO Stock - Frequently Asked Questions

Should I buy or sell NeoGenomics stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last twelve months. There are currently 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NEO shares.
View NEO analyst ratings
or view top-rated stocks.

What is NeoGenomics' stock price forecast for 2023?

12 Wall Street analysts have issued 1 year price objectives for NeoGenomics' shares. Their NEO share price forecasts range from $12.00 to $30.00. On average, they predict the company's stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 58.2% from the stock's current price.
View analysts price targets for NEO
or view top-rated stocks among Wall Street analysts.

How have NEO shares performed in 2022?

NeoGenomics' stock was trading at $34.12 at the start of the year. Since then, NEO shares have decreased by 64.8% and is now trading at $12.01.
View the best growth stocks for 2022 here
.

When is NeoGenomics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our NEO earnings forecast
.

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) issued its quarterly earnings data on Thursday, November, 4th. The medical research company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.09) by $0.01. The medical research company had revenue of $121.30 million for the quarter, compared to analyst estimates of $125.09 million. NeoGenomics had a negative net margin of 32.88% and a negative trailing twelve-month return on equity of 9.46%. The business's revenue was down 3.3% compared to the same quarter last year. During the same period last year, the firm earned $0.04 earnings per share.

What is Douglas M. VanOort's approval rating as NeoGenomics' CEO?

116 employees have rated NeoGenomics Chief Executive Officer Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among the company's employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of NeoGenomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).

What is NeoGenomics' stock symbol?

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

Who are NeoGenomics' major shareholders?

NeoGenomics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.43%), Brown Advisory Inc. (4.89%), State Street Corp (3.34%), First Light Asset Management LLC (2.15%), Emerald Advisers LLC (1.70%) and Federated Hermes Inc. (1.64%). Insiders that own company stock include Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lawrence Martin Weiss, Mark Mallon, Oort Douglas M Van, Robert J Shovlin, Steven C Jones and William Bonello.
View institutional ownership trends
.

How do I buy shares of NeoGenomics?

Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NeoGenomics' stock price today?

One share of NEO stock can currently be purchased for approximately $12.01.

How much money does NeoGenomics make?

NeoGenomics (NASDAQ:NEO) has a market capitalization of $1.52 billion and generates $484.33 million in revenue each year. The medical research company earns $-8,350,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis.

How many employees does NeoGenomics have?

The company employs 2,000 workers across the globe.

How can I contact NeoGenomics?

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The official website for the company is www.neogenomics.com. The medical research company can be reached via phone at (239) 768-0600, via email at sjones@neogenomics.com, or via fax at 239-690-4237.

This page (NASDAQ:NEO) was last updated on 12/8/2022 by MarketBeat.com Staff